Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Cotton-O'Neil Clinical Research Center
mi
from
Topeka, KA
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Cotton-O'Neil Clinical Research Center
mi
from
Topeka, KA
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Center for Advanced Medical Research
mi
from
Saint Peters, MO
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Center for Advanced Medical Research
mi
from
Saint Peters, MO
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Palm Research Center
mi
from
Las Vegas, NV
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Palm Research Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Manhattan Medical Research
mi
from
New York, NY
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Manhattan Medical Research
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Carteret Medical Group, LLC
mi
from
Morehead City, NC
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Carteret Medical Group, LLC
mi
from
Morehead City, NC
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Prestige Clinical Research
mi
from
Franklin, OH
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Prestige Clinical Research
mi
from
Franklin, OH
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Lynn Institute of the Oz
mi
from
Norman, OK
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Lynn Institute of the Oz
mi
from
Norman, OK
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Health Sciences Center
mi
from
Memphis, TN
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Health Sciences Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Dallas Diabetes and Endocrine Center
mi
from
Dallas, TX
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Dallas Diabetes and Endocrine Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Juno Research
mi
from
Houston, TX
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Juno Research
mi
from
Houston, TX
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Panacea Clinical Research
mi
from
San Antonio, TX
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Panacea Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Victorium Clinical Research
mi
from
San Antonio, TX
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Victorium Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Epocrates Medical and Research Center
mi
from
Miami, FL
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Epocrates Medical and Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
LION Research
mi
from
Norman, OK
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
LION Research
mi
from
Norman, OK
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
International Research Associates, LLC
mi
from
Hialeah, FL
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
International Research Associates, LLC
mi
from
Hialeah, FL
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Sensible Healthcare
mi
from
Ocoee, FL
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc.
mi
from
Saint Louis, MO
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc.
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Accent Clinical Trials
mi
from
Las Vegas, NV
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Accent Clinical Trials
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Coastal Bend Clinical Research
mi
from
Corpus Christi, TX
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Coastal Bend Clinical Research
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Sante Clinical Research
mi
from
Kerrville, TX
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Sante Clinical Research
mi
from
Kerrville, TX
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Erickson Research and Development
mi
from
Clinton, UT
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Erickson Research and Development
mi
from
Clinton, UT
Click here to add this to my saved trials
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated:  12/31/1969
Novel Research of New York, LLC
mi
from
Bronx, NY
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Status: Enrolling
Updated: 12/31/1969
Novel Research of New York, LLC
mi
from
Bronx, NY
Click here to add this to my saved trials
Effect of DPP4 Inhibition on Vasoconstriction
Contribution of Neuropeptide Y (NPY) to Vasoconstriction and Sympathetic Activation in the Setting of Dipeptidyl Peptidase IV (DPP4) Inhibition
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Effect of DPP4 Inhibition on Vasoconstriction
Contribution of Neuropeptide Y (NPY) to Vasoconstriction and Sympathetic Activation in the Setting of Dipeptidyl Peptidase IV (DPP4) Inhibition
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
Status: Enrolling
Updated:  12/31/1969
Scripps Whittier Diabetes Institute
mi
from
La Jolla, CA
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings
Status: Enrolling
Updated: 12/31/1969
Scripps Whittier Diabetes Institute
mi
from
La Jolla, CA
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gold River, CA
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gold River, CA
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenbrae, CA
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lakewood, CO
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pembroke Pines, FL
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boise, ID
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Avon, IN
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Avon, IN
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Franklin, IN
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Franklin, IN
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenfield, IN
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenfield, IN
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mooresville, NC
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mooresville, NC
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greer, SC
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Spartanburg, SC
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
South Jordan, UT
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
South Jordan, UT
Click here to add this to my saved trials
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials